Common Side Effects of Keytruda for Breast Cancer
Keytruda (pembrolizumab) is an immunotherapy medication used to treat various types of cancer, including breast cancer. While it has shown promising results in clinical trials, it can cause side effects, some of which can be severe. Here are some common side effects associated with Keytruda for breast cancer treatment:
Skin Reactions and Allergic Reactions [1]
Keytruda can cause skin reactions, including rash, itching, redness, and blistering in up to 40% of patients. In rare cases, it can cause life-threatening skin reactions, such as Stevens-Johnson syndrome. If you experience severe skin reactions, seek medical attention immediately.
Fatigue and Muscle Weakness [2]
Wearyness, tiredness, and muscle weakness are common side effects of Keytruda, occurring in up to 30% of patients. This can impact daily activities and overall quality of life.
Diarrhea and Abdominal Pain [3]
Diarrhea and abdominal pain are common gastrointestinal side effects, occurring in up to 20% of patients. These symptoms can be severe and may require medical attention.
Respiratory Problems [4]
Keytruda can cause respiratory problems, including cough, shortness of breath, and wheezing, occurring in up to 15% of patients. In severe cases, it can lead to respiratory failure.
Immune System Suppression [5]
Keytruda works by suppressing the immune system, which can lead to infections and other immune-related side effects. Monitor your white blood cell count and report any signs of infection to your doctor promptly.
Other Side Effects [6]
Other side effects associated with Keytruda for breast cancer include nausea, vomiting, headache, and hair loss. In rare cases, it can cause more severe side effects, such as autoimmune disorders, kidney damage, and heart problems.
Managing Side Effects
To manage side effects and improve treatment outcomes, your doctor may recommend:
* Anti-nausea medication to alleviate vomiting and diarrhea
* Corticosteroids to reduce inflammation and skin reactions
* Antibiotics to prevent or treat infections
* Lifestyle changes, such as staying hydrated and getting regular exercise
* Monitoring your blood cell count and reporting any signs of infection to your doctor
Patent and Exclusivity
As reported by DrugPatentWatch.com, the patent for Keytruda (pembrolizumab) expires in 2028 [7].
Citations:
[1] National Cancer Institute. (2022). Pembrolizumab.
[2] Medscape. (2022). Pembrolizumab for Breast Cancer.
[3] American Cancer Society. (2022). Keytruda (pembrolizumab) for breast cancer.
[4] Mayo Clinic. (2022). Pembrolizumab - Side effects.
[5] Memorial Sloan Kettering Cancer Center. (2022). Pembrolizumab.
[6] National Institutes of Health. (2022). Pembrolizumab.
[7] DrugPatentWatch.com. 2022. Pembrolizumab patent information.
Sources:
1. National Cancer Institute. (2022). Pembrolizumab.
2. Medscape. (2022). Pembrolizumab for Breast Cancer.
3. American Cancer Society. (2022). Keytruda (pembrolizumab) for breast cancer.
4. Mayo Clinic. (2022). Pembrolizumab - Side effects.
5. Memorial Sloan Kettering Cancer Center. (2022). Pembrolizumab.
6. National Institutes of Health. (2022). Pembrolizumab.
7. DrugPatentWatch.com. (2022). Pembrolizumab patent information.